Hepatitis B treatment

• Author: admin
• Filed under: Hepatitis
• Date: Oct 30,2008

Today, the treatment of hepatitis B have been clearer, there are two formal anti-viral treatment, is a nucleoside analogues alone suppression of the virus treatment, is a kind of immune regulation and direct antiviral effect of the double Interferon antiviral treatment.

The treatment of hepatitis B has gone through a long process of development, as early as the age of 60 were found on the human hepatitis B virus, in 1992, FDA formally approved interferon for chronic hepatitis B antiviral treatment, became the first treatment of hepatitis B drug. In 1998, the first nucleoside analogues lamivudine drug into the clinical and FDA approved for hepatitis B treatment. In recognition of the limitations, many people believe that genes of hepatitis B (HBV DNA) of the decline in the treatment of hepatitis B or inhibiting effect is a manifestation. Lamivudine treatment HBV DNA levels decreased significantly compared with that of interferon and hepatitis B treatment of HBV DNA when the decline is slower, so there are a lot of people gave up the classic interferon antiviral drugs, and the choice of Lamy Stavudine such treatment. However, not last, with the increase in the number of drug, lamivudine treatment of the defect will soon be exposed, long after the treatment, many patients have been effective in the treatment, lamivudine is no longer valid, And even in some patients after the drug also appeared in a major outbreak of hepatitis, when people realize, lamivudine alone can restrain the virus can not clear the virus, to accept the drug-treated patients must take a long time, Moreover, with the use of the extension of the time, the drug-induced variation of the virus will be more and more, people no longer look interferon, into some low rate of drug resistance in the research and development. Clinical treatment to return to the long-lasting remission or suppression of the conflicts among the choices.

Today, the treatment of hepatitis B have been clearer, there are two formal anti-viral treatment, is a nucleoside analogues alone suppression of the virus treatment, is a kind of immune regulation and direct antiviral effect of the double Interferon antiviral treatment.

Nucleoside analogues are characterized by directly inhibiting the virus, but also a very strong inhibition, drug use after a very rapid decline in HBV DNA, but such drugs also has its obvious shortcomings, it is that they can suppress the virus can not clear the virus, long-term use There are variations of the risk of resistance, and along with the extension of the time drug resistant variant of the higher proportion, so that once this type of drug for the treatment of choice, we must take in order to maintain long-term suppression of the role can not stop, Once the drug, inhibition of the drug will stop, the disease could rebound, or even face the danger of outbreak of hepatitis. Interferon for the treatment program have no such problems with interferon and direct regulation of the immune anti-viral dual role of interferon therapy in particular, the role of immune regulation will continue to exist after the end of the treatment, so its effect is more durable, relapse Lower rate, along with their regular course of treatment, there is no risk of resistance, is currently in the choice of treatment options, particularly in the emergence of new pegylated interferon, the clinical treatment of interferon is often the first to try to pursue a lasting Remission, and then the failure of interferon treatment for the treatment of nucleoside analogues.

Restrictions on the past interferon efficacy of the most important reason is that traditional interferon (also known as interferon general) was too short half-life in blood concentrations of instability, the concentration increased soon after the injection, but soon fell, the concentration of excessive side effects Would be too large, they will not achieve the low concentration of the corresponding treatment. Later, as the bio-pharmaceutical technology, polyethylene glycol-based technologies are applied to improve the interferon, PEG-interferon technology allows the molecular weight has been increased so that the interferon to be significantly longer half-life, blood Concentration become more stable (at this point of 40KD pegylated interferon a-2a more obvious), which can significantly improve the clinical efficacy (from 12% to 32% or so), but also interfere with polyethylene glycol -Treatment of hepatitis B to become the new hot spots.

Related Reviews:

• Treatment of hepatitis B have a right direction (0)
• Anti-hepatitis B pay attention to “individual” (0)
• Analysis of the likely negative hepatitis B (0)
• Young people have a strategy of anti-hepatitis B (0)
• Hepatitis B refractory to solve the “mystery” (0)